Journal ArticleDOI
Potential role of rituximab in metastatic castrate-resistant prostate cancer.
Reads0
Chats0
TLDR
A case of a patient who achieved remission of metastatic castrate-resistant prostate cancer after receiving rituximab and bendamustine for the treatment of follicular lymphoma is presented.Abstract:
Nearly all men with prostate cancer who are treated with androgen deprivation therapy develop disease progression. There is considerable evidence to suggest that CXCL 13 released by tumor cells leads to B-cell infiltration into the prostate cells. This B-cell infiltration has been postulated to play a role in development of disease progression following androgen-deprivation therapies. We present a case of a patient who achieved remission of metastatic castrate-resistant prostate cancer after receiving rituximab and bendamustine for the treatment of follicular lymphoma. The findings in this report suggest that further investigation is warranted for utilizing B-cell targeted therapy in delaying progression of castrate-resistant prostate cancer.read more
Citations
More filters
Journal ArticleDOI
NF-κB signaling promotes castration-resistant prostate cancer initiation and progression
TL;DR: Evidence that NF-κB signaling promotes CRPCa initiation and progression is presented, the dichotomic role of NF- ΚB in the regulation of AR expression and activity is described and studies that explore NF-σκB inhibitors as PCa therapies are outlined.
Journal ArticleDOI
Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer
Stephen Ryan,Jing Zhang,Danielle Burner,Michael A. Liss,Emily Pittman,Michelle Muldong,Ahmed Shabaik,Jason Woo,Nicole Basler,Jonathan Cunha,Shabnam Shalapour,Monica V. Estrada,Michael Karin,Karen Messer,Stephen H. Howell,Christopher J. Kane,Christina Jamieson +16 more
TL;DR: This is the first study to treat patients prior to surgical prostate removal with an immunotherapy that targets B-cells, demonstrating inter-dependence between B- and T-cells in prostate cancer and that Rituximab can modify the immune environment in prostate tumors.
Journal ArticleDOI
Revisiting prostate cancer metabolism: From metabolites to disease and therapy
Henrique J. Cardoso,Tiago M.A. Carvalho,Lara R. S. Fonseca,Marília I. Figueira,Cátia V. Vaz,Sílvia Socorro +5 more
TL;DR: In this paper, the status of prostate cancer treatment based on the inhibition of metabolic pathways is presented, highlighting the critical metabolic alterations that could have a clinical and therapeutic interest, and the role of bioenergetic sources, namely, glucose, lipids, and glutamine sustaining PCa cell survival and growth.
Journal ArticleDOI
Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer
Frank Waldbillig,Katja Nitschke,Abdallah Abdelhadi,Jost von Hardenberg,Philipp Nuhn,Malin Nientiedt,Cleo Aron Weis,Maurice Stephan Michel,Philipp Erben,Thomas Stefan Worst +9 more
TL;DR: SMPLD3B is highly overexpressed in PCa tissue, is inversely associated with localized PCa prognosis, and impairs PCa cell migration.
Book ChapterDOI
Chapter 9. Field Discoveries (Case Reports)
TL;DR: In this article , the authors follow the process by which field discoveries made by clinicians in their everyday practice are diffused, validated in larger trials, and adopted into clinical practice through real-world drug repurposing (off-label use), sometimes gaining regulatory approval.
References
More filters
Journal ArticleDOI
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Ian F. Tannock,Ronald de Wit,William R. Berry,Jozsef Horti,Anna Pluzanska,Kim N. Chi,Stéphane Oudard,Christine Theodore,Nicholas D. James,Ingela Turesson,Mark Rosenthal,Mario A. Eisenberger +11 more
TL;DR: When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.
Journal ArticleDOI
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono,Christopher J. Logothetis,Arturo Molina,Karim Fizazi,Scott North,Luis Chu,Kim N. Chi,Robert Jones,Oscar B. Goodman,Fred Saad,John Staffurth,Paul N. Mainwaring,S. J. Harland,Thomas W. Flaig,Thomas E. Hutson,Tina Cheng,Helen Patterson,John D. Hainsworth,Charles J. Ryan,Cora N. Sternberg,Susan Ellard,Aude Flechon,Mansoor N. Saleh,Mark C. Scholz,Eleni Efstathiou,Andrea Zivi,Diletta Bianchini,Yohann Loriot,Nicole Chieffo,Thian Kheoh,Christopher M. Haqq,Howard I. Scher +31 more
TL;DR: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.
Journal ArticleDOI
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher,Karim Fizazi,Fred Saad,Mary-Ellen Taplin,Cora N. Sternberg,Kurt Miller,Ronald de Wit,Peter F.A. Mulders,Kim N. Chi,Neal D. Shore,Andrew J. Armstrong,Thomas W. Flaig,Aude Flechon,Paul N. Mainwaring,Mark D. Fleming,John D. Hainsworth,Mohammad Hirmand,Bryan Selby,Lynn Seely,Johann S. de Bono,B Ch +20 more
TL;DR: Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy, and was shown with respect to all secondary end points.
Journal ArticleDOI
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
Daniel P. Petrylak,Catherine M. Tangen,Maha Hussain,Primo N. Lara,Jeffrey A. Jones,Mary-Ellen Taplin,Patrick A. Burch,Donna L. Berry,Carol M. Moinpour,Manish Kohli,Mitchell C. Benson,Eric J. Small,Derek Raghavan,E. David Crawford +13 more
TL;DR: The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.
Journal ArticleDOI
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
Dominik Berthold,Gregory R. Pond,Freidele Soban,Ronald de Wit,Mario A. Eisenberger,Ian F. Tannock +5 more
TL;DR: It is confirmed that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP, and consistent results are observed across subgroups of patients.
Related Papers (5)
miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer
Noushin Nabavi,Noushin Nabavi,Noushin Nabavi,Nur Ridzwan Nur Saidy,Nur Ridzwan Nur Saidy,Erik Venalainen,Erik Venalainen,Anne Haegert,Abhijit Parolia,Abhijit Parolia,Hui Xue,Hui Xue,Yuwei Wang,Yuwei Wang,Rebecca Wu,Rebecca Wu,Xin Dong,Colin Collins,Francesco Crea,Francesco Crea,Yuzhuo Wang,Yuzhuo Wang,Yuzhuo Wang +22 more